ストックスクリーナーアプリを入手
31.14
1.24%
-0.39
前日終値:
$31.53
開ける：
$31.28
24時間の取引高:
697.99K
Relative Volume:
0.74
時価総額：
$2.51B
収益：
$399.58M
当期純損益:
$-54.04M
株価収益率:
-41.52
EPS:
-0.75
ネットキャッシュフロー:
$40.13M
1週間 パフォーマンス:
+2.94%
1か月 パフォーマンス:
-0.29%
6か月 パフォーマンス:
-9.24%
1年 パフォーマンス:
+65.11%
1日の値動き範囲:
$30.77
$31.34
1週間の範囲:
$29.54
$32.76
52週間の値動き範囲:
$18.61
$47.32
Veracyte Inc Stock (VCYT) Company Profile
名前
Veracyte Inc
セクター
電話
(650) 243-6300
住所
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
VCYT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
31.14 | 2.51B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-20 | 開始されました | Craig Hallum | Buy |
| 2024-12-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-16 | 開始されました | UBS | Buy |
| 2024-10-10 | 開始されました | Guggenheim | Buy |
| 2024-02-23 | 繰り返されました | Needham | Buy |
| 2023-01-18 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2021-11-18 | 再開されました | Goldman | Buy |
| 2021-06-15 | 開始されました | Raymond James | Outperform |
| 2021-02-18 | 再開されました | Needham | Buy |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2019-07-31 | 開始されました | Lake Street | Buy |
| 2019-07-02 | 開始されました | Needham | Buy |
| 2018-11-29 | ダウングレード | Janney | Buy → Neutral |
| 2018-10-31 | アップグレード | Janney | Neutral → Buy |
| 2017-11-07 | ダウングレード | Janney | Buy → Neutral |
| 2017-11-07 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 再開されました | BTIG Research | Buy |
| 2016-11-14 | 再開されました | Leerink Partners | Outperform |
| 2015-12-18 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-06-11 | 繰り返されました | Leerink Partners | Outperform |
| 2013-11-26 | 開始されました | William Blair | Outperform |
すべてを表示
Veracyte Inc (VCYT) 最新ニュース
Should You Continue to Hold Veracyte Stock in Your Portfolio? - Yahoo Finance
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 | VCYT Stock News - GuruFocus
Cancer Diagnostics Leader Veracyte Announces Q1 2025 Earnings Date: Key Updates Coming May 7 - Stock Titan
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Here's Why Veracyte (VCYT) is a Strong Growth Stock - Yahoo Finance
Veracyte And 2 More Stocks That Might Be Trading Below Their Estimated Value - Yahoo Finance
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago - MSN
Veracyte (VCYT) Just Overtook the 20-Day Moving Average - Yahoo Finance
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? - Nasdaq
Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating By Investing.com - Investing.com South Africa
Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating - Investing.com Australia
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Veracyte Scores Relative Strength Rating Upgrade; Hits Key Threshold - MSN
Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever! - Insider Monkey
9 AI News and Ratings on Investors’ Radar - Insider Monkey
Craig-Hallum bullish on Veracyte, initiates with a Buy - MSN
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade - Yahoo
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - 01net
Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests - MarketScreener
Veracyte (VCYT) Shares Cross Above 200 DMA - Nasdaq
Veracyte says new data demonstrate accuracy of WGS-based platform - TipRanks
New Data Demonstrate Accuracy Of Veracyte's Whole-Genome Sequencing-Based Mrd Testing Platform For Muscle-Invasive Bladder Cancer - Marketscreener.com
5 Analysts Assess Veracyte: What You Need To Know - Benzinga
Craig-Hallum initiates Veracyte stock with Buy, sets $45 target By Investing.com - Investing.com South Africa
Craig-Hallum initiates Veracyte stock with Buy, sets $45 target - Investing.com India
Craig-Hallum Initiates Veracyte at Buy With $45 Price Target -March 20, 2025 at 07:28 am EDT - Marketscreener.com
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 - BioSpace
Veracyte's Decipher, MRD tests highlights to be presented at EAU25 -March 19, 2025 at 05:05 pm EDT - Marketscreener.com
Veracyte's Cancer Detection Tests Prove Powerful in Major Clinical StudiesNew Product Coming - StockTitan
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally? - Yahoo Finance
Analyst Sees Bottom For Myriad Genetics Stock, Issues UpgradeMyriad Genetics (NASDAQ:MYGN) - Benzinga
Veracyte’s chief commercial officer John Leite sells $234,629 in stock By Investing.com - Investing.com Canada
Veracyte’s chief commercial officer John Leite sells $234,629 in stock - Investing.com
Veracyte (VCYT) Surged on Reporting Strong Earnings - Insider Monkey
Veracyte Inc to Host Earnings Call - ACCESS Newswire
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality - Simply Wall St
29,779 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Proficio Capital Partners LLC - Defense World
Insider Sell: Phillip Febbo Sells Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte at Raymond James Conference: Strategic Expansion and Growth By Investing.com - Investing.com Australia
Veracyte Inc (VCYT) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
大文字化:
|
ボリューム (24 時間):